Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipram is a brand name for pancrelipase, a porcine-derived pancreatic enzyme replacement therapy (PERT). It consists of a mixture of digestive enzymes, including lipase, amylase, and protease, which are essential for the digestion of fats, carbohydrates, and proteins. Lipram is specifically indicated for the treatment of exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough enzymes to properly digest food. This condition is frequently associated with cystic fibrosis, chronic pancreatitis, pancreatectomy, or other gastrointestinal surgeries. The medication is typically formulated as enteric-coated capsules to prevent the enzymes from being inactivated by gastric acid, allowing them to be released in the duodenum where they facilitate nutrient absorption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancrelipase (Impax Laboratories).